I held some 150c options through data (even though you should never hold through data, no matter what) just to keep a toe in the water and see how it all plays out.

I am no scientist, but they seem to have done what they set out to do - show improved cognition at 9 months of treatment on simulfilam.  It was 18% vs 10% in the 6 month readout.

There were massive expectations built into this event and data readout.  I think, no matter what, it was going to be a sell the news event.

I don't think SAVA's story is over.  Far from it.  Unless I'm reading the data incorrectly, there's a lot of upside for the company here (valuations aside).  If the data is real, I don't see how a bigger pharma doesn't come in and either buy them or do a partnership (most likely).  

I've still got three weeks left on the options, so I'm going to sit tight and see if there's an extra scene in the credits.